HLA-DOB

Summary

HLA-DOB (major histocompatibility complex, class II, DO beta, HGNC:4937) is a protein-coding gene on chromosome 6p21.32, encoding HLA class II histocompatibility antigen, DO beta chain (P13765). Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells.

HLA-DOB belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DOA) and a beta chain (DOB), both anchored in the membrane. It is located in intracellular vesicles. DO suppresses peptide loading of MHC class II molecules by inhibiting HLA-DM. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail.

Source: NCBI Gene 3112 — RefSeq curated summary.

At a glance

• GWAS associations: 28
• Clinical variants (ClinVar): 6 total
• MANE Select transcript: NM_002120

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4937
Approved symbol	HLA-DOB
Name	major histocompatibility complex, class II, DO beta
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000241106
Ensembl biotype	protein_coding
OMIM	600629
Entrez	3112

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000438763, ENST00000447394, ENST00000475235, ENST00000488325, ENST00000648009, ENST00000900286, ENST00000944925

RefSeq mRNA: 1 — MANE Select: NM_002120 NM_002120

CCDS: CCDS4754

Canonical transcript exons

ENST00000426644 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 96.70.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.7222 / max 515.6970, expressed in 144 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73015	2.6799	137
73016	0.0297	12
73017	0.0127	6

Top tissues by expression

136 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lymph node	UBERON:0000029	96.70	gold quality
spleen	UBERON:0002106	94.35	gold quality
vermiform appendix	UBERON:0001154	91.45	gold quality
granulocyte	CL:0000094	90.93	gold quality
bone marrow cell	CL:0002092	87.49	gold quality
blood	UBERON:0000178	84.78	gold quality
lower esophagus mucosa	UBERON:0035834	83.23	gold quality
bone marrow	UBERON:0002371	82.51	gold quality
tonsil	UBERON:0002372	81.93	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.76	gold quality
small intestine Peyer’s patch	UBERON:0003454	80.39	gold quality
leukocyte	CL:0000738	79.66	gold quality
monocyte	CL:0000576	78.49	gold quality
small intestine	UBERON:0002108	78.31	gold quality
rectum	UBERON:0001052	78.18	gold quality
endometrium	UBERON:0001295	78.04	gold quality
gall bladder	UBERON:0002110	74.64	gold quality
saliva-secreting gland	UBERON:0001044	74.30	gold quality
mucosa of transverse colon	UBERON:0004991	74.27	gold quality
minor salivary gland	UBERON:0001830	74.24	gold quality
duodenum	UBERON:0002114	72.78	gold quality
right lung	UBERON:0002167	72.45	gold quality
upper lobe of left lung	UBERON:0008952	72.32	gold quality
adenohypophysis	UBERON:0002196	71.48	gold quality
esophagus mucosa	UBERON:0002469	71.20	gold quality
skin of leg	UBERON:0001511	70.39	gold quality
zone of skin	UBERON:0000014	70.36	gold quality
skin of abdomen	UBERON:0001416	70.29	gold quality
pituitary gland	UBERON:0000007	69.99	gold quality
quadriceps femoris	UBERON:0001377	69.42	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	68.21
E-ANND-3	yes	14.34
E-MTAB-6678	yes	8.67
E-MTAB-8410	no	0.94

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CIITA, CREB1, POU2F2, RFX1, RFX5, RFXANK, RFXAP

miRNA regulators (miRDB)

64 targeting HLA-DOB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6857-5P	99.87	65.32	985

Literature-anchored findings (GeneRIF, showing 9)

• HLA-DOB mutations were analyzed for association with autoimmune diseases and B-cell leukemias. (PMID:12439622)
• In transgenic mice expressing human HLA-DOA & HLA-DOB from a DC-specific promoter, as DO increased, A(b)-CLIP increased & class II-peptides decreased. DO impaired H-2M function, causing Ag-specific downmodulation of class II Ag processing/presentation. (PMID:15265882)
• A new DOB allele, DOB*010103, was identified in the Korean population during sequence-based HLA-DOB typing. (PMID:15730525)
• results show that HLA-DO inhibits HLA-DM function by acting as a substrate mimic, and the findings also limit the possible functional roles for HLA-DO in antigen presentation (PMID:23222639)
• HLA-DO beta-chain antigens are ubiquitinated by MARCH family E3 ligases 1, 8, and 9. (PMID:23400868)
• TAP2, HLA-DOA, HLA-DOB, and tapasin loci are novel candidate regions for susceptibility to HCV infection and viral clearance in the Chinese population (PMID:25874709)
• results indicate that HLA-DOB is co-inherited with DQA2-B2 genes and thus may contribute to HCV and HBV persistence (PMID:28813660)
• MUC22, HLA-A, and HLA-DOB variants and COVID-19 in resilient super-agers from Brazil. (PMID:36389712)
• Potential role of SNP rs2071475 in rheumatoid arthritis and inflammatory bowel disease in the East Asian population: a Mendelian randomization study. (PMID:37855981)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	H2-Ob	ENSMUSG00000041538
rattus_norvegicus	RT1-DOb	ENSRNOG00000000454

Paralogs (13): B2M (ENSG00000166710), HLA-DQB1 (ENSG00000179344), HLA-DRB1 (ENSG00000196126), HLA-DQA1 (ENSG00000196735), HLA-DRB5 (ENSG00000198502), HLA-DOA (ENSG00000204252), HLA-DMA (ENSG00000204257), HLA-DRA (ENSG00000204287), HLA-DPB1 (ENSG00000223865), HLA-DPA1 (ENSG00000231389), HLA-DQB2 (ENSG00000232629), HLA-DQA2 (ENSG00000237541), HLA-DMB (ENSG00000242574)

Protein

Protein identifiers

HLA class II histocompatibility antigen, DO beta chain — P13765 (reviewed: P13765)

Alternative names: MHC class II antigen DOB

All UniProt accessions (4): E9PI00, P13765, H0Y4X4, Q5QNS2

UniProt curated annotations — full annotation on UniProt →

Function. Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM.

Subunit / interactions. Heterodimer of an alpha chain (DOA) and a beta chain (DOB). Forms a heterotetrameric complex with an HLA-DM molecule during intracellular transport in endosomal/lysosomal compartments in B-cells.

Subcellular location. Endosome membrane. Lysosome membrane.

Polymorphism. The following alleles of DOB are known: DOB01:01, DOB01:02, DOB01:03 and DOB01:04. The sequence shown is that of DOB*01:01.

Similarity. Belongs to the MHC class II family.

RefSeq proteins (1): NP_002111* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000353	MHC_II_b_N	Domain
IPR003006	Ig/MHC_CS	Conserved_site
IPR003597	Ig_C1-set	Domain
IPR007110	Ig-like_dom	Domain
IPR011162	MHC_I/II-like_Ag-recog	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014745	MHC_II_a/b_N	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050160	MHC/Immunoglobulin	Family

Pfam: PF00969, PF07654

UniProt features (36 total): strand 12, helix 5, sequence variant 4, turn 3, region of interest 3, disulfide bond 2, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, domain 1, glycosylation site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4I0P	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13765-F1	87.44	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 41–105, 143–199

Glycosylation sites (1): 45

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2132295	MHC class II antigen presentation

MSigDB gene sets: 274 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_OR_POLYSACCHARIDE_ANTIGEN_VIA_MHC_CLASS_II, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOCC_VACUOLAR_MEMBRANE, GOBP_REGULATION_OF_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_ANTIGEN, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_ANTIGEN, MODULE_143, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, KEGG_VIRAL_MYOCARDITIS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, KEGG_TYPE_I_DIABETES_MELLITUS, GOBP_REGULATION_OF_ANTIGEN_PROCESSING_AND_PRESENTATION, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5

GO Biological Process (10): adaptive immune response (GO:0002250), peptide antigen assembly with MHC class II protein complex (GO:0002503), negative regulation of antigen processing and presentation of peptide antigen via MHC class II (GO:0002587), antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886), positive regulation of immune response (GO:0050778), positive regulation of T cell activation (GO:0050870), immune system process (GO:0002376), antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (GO:0002504), immune response (GO:0006955), antigen processing and presentation (GO:0019882)

GO Molecular Function (3): MHC class II protein complex binding (GO:0023026), MHC class II receptor activity (GO:0032395), peptide antigen binding (GO:0042605)

GO Cellular Component (7): lysosome (GO:0005764), lysosomal membrane (GO:0005765), late endosome membrane (GO:0031902), MHC class II protein complex (GO:0042613), endosome (GO:0005768), endosome membrane (GO:0010008), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
antigen processing and presentation of peptide antigen via MHC class II	3
immune response	2
immune system process	2
MHC class II protein complex assembly	1
peptide antigen assembly with MHC protein complex	1
negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	1
negative regulation of antigen processing and presentation of peptide antigen	1
regulation of antigen processing and presentation of peptide antigen via MHC class II	1
antigen processing and presentation of exogenous peptide antigen	1
positive regulation of immune system process	1
positive regulation of response to stimulus	1
regulation of immune response	1
T cell activation	1
regulation of T cell activation	1
positive regulation of lymphocyte activation	1
positive regulation of leukocyte cell-cell adhesion	1
biological_process	1
antigen processing and presentation	1
response to stimulus	1
MHC protein complex binding	1
transmembrane signaling receptor activity	1
MHC class II protein binding	1
immune receptor activity	1
antigen binding	1
peptide binding	1
lytic vacuole	1
lysosome	1
lytic vacuole membrane	1
late endosome	1
endosome membrane	1
MHC protein complex	1
endomembrane system	1
cytoplasmic vesicle	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HLA-DOB	PSMB9	P28065	839
HLA-DOB	HLA-DMA	P28067	835
HLA-DOB	PSMB8	P28062	832
HLA-DOB	HLA-B	P01889	549
HLA-DOB	HLA-DQA2	P01906	527
HLA-DOB	HLA-C	P04222	501
HLA-DOB	HLA-DOA	P06340	486
HLA-DOB	TAP1	Q03518	476
HLA-DOB	TNF	P01375	473
HLA-DOB	HLA-DMB	P28068	465
HLA-DOB	RING1	Q06587	460
HLA-DOB	LILRB1	Q8NHL6	436
HLA-DOB	PBX2	P40425	429
HLA-DOB	BRD2	P25440	426
HLA-DOB	HLA-DRA	P01903	426

IntAct

7 interactions, top by confidence:

A	B	Type	Score
HLA-DMA	HLA-DOA	psi-mi:“MI:0915”(physical association)	0.590
HLA-DMA	HLA-DOA	psi-mi:“MI:0407”(direct interaction)	0.590
HLA-DMA	HLA-DOA	psi-mi:“MI:0914”(association)	0.590
HLA-DOA	HLA-DOB	psi-mi:“MI:0407”(direct interaction)	0.440
CDKN2A	HLA-DOB	psi-mi:“MI:0915”(physical association)	0.370
SLC22A14	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (4): HLA-DOB (Two-hybrid), HLA-DOB (Affinity Capture-Western), HLA-DOB (Affinity Capture-Western), HLA-DOB (Affinity Capture-MS)

ESM2 similar proteins: C1ITJ8, O19477, O35799, P01901, P01902, P01920, P01921, P04440, P05538, P06339, P06341, P06342, P06343, P06344, P06345, P06346, P13765, P14428, P14429, P14432, P14483, P15464, P15979, P15982, P15983, P16391, P18467, P18469, P18470, P23068, P25311, P29826, P60018, P70387, Q29980, Q29983, Q2KN22, Q30201, Q5RD09, Q63678

Diamond homologs: C1ITJ8, O19477, O35799, P01888, P01889, P01893, P01894, P01895, P01896, P01897, P01898, P01899, P01900, P01901, P01902, P03991, P04223, P04439, P06126, P06140, P06339, P10321, P13747, P13748, P13749, P13750, P13751, P13752, P13753, P13765, P14426, P14427, P14428, P14429, P14430, P14431, P14432, P15464, P15978, P15979

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CIITA	“up-regulates quantity by expression”	HLA-DOB	“transcriptional regulation”
RFX1	“up-regulates quantity by expression”	HLA-DOB	“transcriptional regulation”
“RFX complex”	“up-regulates quantity by expression”	HLA-DOB	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

6 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1142 predictions. Top by Δscore:

Variant	Effect	Δscore
6:32814318:A:AC	donor_gain	1.0000
6:32814319:C:CC	donor_gain	1.0000
6:32814319:CTCCA:C	donor_gain	1.0000
6:32814602:C:CC	acceptor_gain	1.0000
6:32816855:TCTTA:T	donor_loss	1.0000
6:32816856:CTTA:C	donor_loss	1.0000
6:32816856:CTTAC:C	donor_loss	1.0000
6:32816857:TTACC:T	donor_loss	1.0000
6:32816858:TA:T	donor_loss	1.0000
6:32816858:TAC:T	donor_loss	1.0000
6:32816859:A:C	donor_loss	1.0000
6:32816859:ACC:A	donor_loss	1.0000
6:32816860:C:G	donor_loss	1.0000
6:32816948:CCATT:C	acceptor_gain	1.0000
6:32816949:CATT:C	acceptor_gain	1.0000
6:32816949:CATTC:C	acceptor_gain	1.0000
6:32816951:TT:T	acceptor_gain	1.0000
6:32816953:C:CC	acceptor_gain	1.0000
6:32814318:ACT:A	donor_gain	0.9900
6:32814319:CT:C	donor_gain	0.9900
6:32814319:CTC:C	donor_gain	0.9900
6:32814344:G:C	donor_gain	0.9900
6:32814437:T:TA	donor_gain	0.9900
6:32814598:TGCA:T	acceptor_gain	0.9900
6:32814599:GCA:G	acceptor_gain	0.9900
6:32814600:CA:C	acceptor_gain	0.9900
6:32814600:CAC:C	acceptor_gain	0.9900
6:32815039:CTCA:C	donor_loss	0.9900
6:32815040:TCA:T	donor_loss	0.9900
6:32815041:CA:C	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000128687 (6:32813181 T>A), RS1000928748 (6:32817209 G>A), RS1001263464 (6:32813110 G>A,C), RS1001337250 (6:32813385 C>G,T), RS1001411351 (6:32812377 G>A), RS1002209984 (6:32818667 G>A), RS1002985913 (6:32814583 A>G), RS1004645921 (6:32812331 G>C), RS1004715638 (6:32813051 A>T), RS1005390150 (6:32815815 A>G), RS1005751947 (6:32817152 A>G), RS1005914119 (6:32816468 G>A), RS1006495814 (6:32814897 G>A,C), RS1006792093 (6:32814503 T>C), RS1007072196 (6:32817294 T>C)

Disease associations

OMIM: gene MIM:600629 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST001455_2	Kawasaki disease	5.000000e-11
GCST001785_9	Crohn’s disease	9.000000e-59
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_170	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_296	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST004748_116	Lung cancer	1.000000e-11
GCST004749_11	Lung cancer in ever smokers	1.000000e-10
GCST004750_63	Squamous cell lung carcinoma	2.000000e-10
GCST005541_24	Sarcoidosis (Lofgren’s syndrome vs non-Lofgren’s syndrome)	4.000000e-11
GCST006575_22	Takayasu arteritis	2.000000e-10
GCST006867_50	Type 2 diabetes	7.000000e-11
GCST007201_152	Schizophrenia	4.000000e-12
GCST007564_33	Asthma or allergic disease (pleiotropy)	8.000000e-35
GCST008916_16	Asthma	3.000000e-17
GCST008916_27	Asthma	5.000000e-31
GCST008916_90	Asthma	4.000000e-15
GCST008921_2	Asthma and major depressive disorder	3.000000e-13
GCST010979_15	Kawasaki disease	7.000000e-13
GCST011940_11	Bullous pemphigoid	7.000000e-06
GCST012227_798	Hip circumference adjusted for BMI	2.000000e-10
GCST012228_259	Waist-hip index	3.000000e-14
GCST012230_444	Waist-to-hip ratio adjusted for BMI	1.000000e-15
GCST012231_216	A body shape index	1.000000e-08
GCST90002388_83	Lymphocyte count	1.000000e-11
GCST90020024_1108	A body shape index	1.000000e-09
GCST90020024_1112	A body shape index	3.000000e-09
GCST90020028_1278	Hip circumference adjusted for BMI	9.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0007789	BMI-adjusted waist circumference
EFO:0004587	lymphocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2071554	HLA-DOB		0.00	0

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
Nickel	increases expression	2
TL8-506	affects cotreatment, increases expression	1
Meropenem	affects expression	1
Aldehydes	increases expression	1
Benzalkonium Compounds	affects response to substance	1
Hydralazine	affects cotreatment, increases expression	1
Poly I-C	increases expression, affects cotreatment	1
Tobacco Smoke Pollution	increases expression	1
Trimethoprim	affects expression	1
Valproic Acid	affects cotreatment, increases expression	1
Mifepristone	decreases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C5VJ	LG2 DO-KO-1	Transformed cell line	Male
CVCL_C5VK	LG2 DO-KO-2	Transformed cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.